Clinical Trial

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Study acronym: TUC-TOC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-07-20; most recent amendment 2025-03-26.
Status change: Active, Not Recruiting → Recruiting 2024-01-24
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-12-19
Trial Details
NCT Number NCT05955170
Lead Sponsor Institut Curie
Collaborators: Seagen Inc.
Conditions HER2-positive Breast Cancer
Enrollment 66 participants
Start Date 2023-12-19
Primary Completion 2027-12-19 (estimated)
Study Completion 2028-12-19 (estimated)
Updated on ClinicalTrials.gov 2025-03-27